Jen Norton
President, Market Access & Value, EVERSANA
Expertise:
Jen leads EVERSANA’s market access, pricing, and reimbursement strategies, helping life sciences innovators overcome barriers to drug access and affordability. With more than two decades of leadership in the pharmaceutical market access landscape, Jen brings deep therapeutic expertise across specialty products, biosimilars, oncology, and rare diseases. Prior to EVERSANA, she served as Senior Vice President of US Patient and Market Access at Takeda Pharmaceuticals and Vice President and Head of US Value and Access at Amgen, where she led critical payer negotiations and patient support organizations. She is an active industry leader, currently serving as the 2025 Board Chair for the National Pharmaceutical Council (NPC), and is a dedicated volunteer for community food nonprofits across the country.
Articles by Jen Norton
The Industry Doesn’t Have an Access Collaboration Problem. It Has an Accountability Problem.
Who should own market access? Today, market access is no longer a solo responsibility. Access outcomes are shaped by decisions made across nearly every corporate function—from R&D to regulatory to trade and channel to field reimbursement. Yet many organizations still operate in silos, acquiring “access debt.” Every decision can create reimbursement, affordability, or distribution barriers that don’t emerge until launch. In this article, President of Market Access & Value, Jen Norton, explores: Why access collaboration alone is no longer […]